Tissue Regenix Group is thrilled to announce a successful funding round in which the company raised £70,000,000, a milestone that will accelerate its mission to revolutionize regenerative medicine worldwide. Founded in 2006 as a spin-out from the University of Leeds, Tissue Regenix has emerged as a leading medical devices company driven by innovation, cutting-edge technology, and a commitment to transforming patient care. The new funding will mainly be allocated to expanding its pioneering dCELL® technology—a patented decellularisation process that removes DNA and cellular remnants from animal and human soft tissue. This process creates an acellular scaffold that is biologically compatible with the patient, enabling effective repair of damaged tissues and addressing critical clinical needs in sports medicine, heart valve replacement, and wound care.
The company’s ambitious growth strategy is further bolstered by its worldwide presence and its targeted investments, such as the establishment of Tissue Regenix Wound Care Inc. in the United States (now rebranded as TRX BioSurgery) and its joint venture GBM-V in Rostock, Germany, which underlines its commitment to advancing tissue banking and regenerative therapies. Additionally, Tissue Regenix’s strategic acquisition of CellRight Technologies® in August 2017 has strengthened its portfolio in developing osteoinductive and wound care scaffolds for a wide range of surgical applications spanning spine, trauma, general orthopedics, foot and ankle, dental procedures, and sports medicine. With this substantial new capital, Tissue Regenix Group is poised to invest in R&D, expand its global footprint, and further establish itself as a leader in innovative regenerative solutions that enhance healing and improve patient outcomes.
